AZD 1236

Drug Profile

AZD 1236

Alternative Names: AZD1236

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 29 Jul 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in Japan (PO)
  • 29 Jul 2010 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Europe (PO)
  • 31 Jul 2007 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top